Cixutumumab

Abstract

The IGF pathway plays a major role in cancer cell proliferation, survival and resistance to antineoplastic therapies in many human malignancies. As such, interference with this pathway is the target of many investigational pharmacologic agents. Cixutumumab, a monoclonal antibody to IGF-1R, utilizes this concept. In this review, we summarize preclinical, pharmacologic and early clinical data regarding this agent and discuss the impact this drug might have on the future treatment of human cancers.

Conflict of interest statement

Declaration of interest

P Haluska receives research funds from ImClone. He is an unpaid consultant for ImClone and Mayo and has received funds for research related to cixutimumab. KP McKian states no conflict of interest and has received no payment in preparation of this manuscript.

Figures

Figure 1. IGF system and regulation

GH: Growth hormone; IGFBP: IGF binding protein.